title: Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.
authors.forename: M
authors.initials: M
authors.lastname: Okamoto
authors.forename: A
authors.initials: A
authors.lastname: Okano
authors.forename: S
authors.initials: S
authors.lastname: Akamatsu
authors.forename: E
authors.initials: E
authors.lastname: Ashihara
authors.forename: T
authors.initials: T
authors.lastname: Inaba
authors.forename: H
authors.initials: H
authors.lastname: Takenaka
authors.forename: N
authors.initials: N
authors.lastname: Katoh
authors.forename: S
authors.initials: S
authors.lastname: Kishimoto
authors.forename: C
authors.initials: C
authors.lastname: Shimazaki
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D017809:Fatal Outcome; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D012307:Risk Factors; D000069283:Rituximab; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D013256:Steroids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D013256:Steroids; D000069283:Rituximab